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Anthracycline- and taxane-based chemotherapy regimens are
active as front- or second-line treatment options in patients with
MBC resulting in high response rates (Gianni et al, 1995; Ravdin
et al, 1995; Conte et al, 1997; Mavroudis et al, 1999). For patients
who have failed to respond or relapse early after the taxane/anthra-
cycline regimens, the prognosis is poor since few drugs are still
active in this setting (Porkka et al, 1994). 
Until the development of new active anticancer agents for the
treatment of refractory MBC, we are compelled to use the avail-
able agents with the most appropriate manner. Recently, there has
been an increasing interest in the treatment of MBC with contin-
uous infusion (c.i.) of 5-fluorouracil (5-FU). Phase II studies of c.i.
5-FU, conducted mainly in heavily pretreated patients, have
demonstrated an objective response rate ranging from 12% to
54%, and a median duration of response up to 6 months (Lokich
et al, 1989; Cameron et al, 1994). Interestingly, the prolonged
infusion of 5-FU was associated with reduced myelotoxicity,
which permits the administration of higher doses of the drug.
Nevertheless, this mode of administration is accompanied by
an increased incidence of stomatitis and palmar-plantar
erythrodysaesthesia. This therapeutic benefit with c.i. of 5-FU has
also been shown in patients with metastatic colorectal cancer
(Lokich et al, 1989). 
Cyclophosphamide (CPM) is an active agent against MBC
given either as first- (ORR = 34%) or second-line (ORR = 22%)
treatment (Piccart et al, 1995). Although the combination of
cyclophosphamide and doxorubicin remains a standard front-line
regimen in MBC, a recent phase III study showed a higher overall
response rate and significantly longer time to disease progression
in favour of the docetaxel/doxorubicin combination as compared
with the combination of doxorubicin/cyclophosphamide
(Nabholtz et al, 1999). Therefore, the number of patients who do
not receive cyclophosphamide and 5-FU in the front-line setting
will be increasing in the future. 
Based on these data, we conducted a phase II study to evaluate
the activity and tolerance of high dose c.i. 5-FU/LV in
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Summary The purpose of this study was to evaluate the activity and tolerance of high-dose leucovorin (LV) and infusional 5-fluorouracil (5-
FU) in combination with conventional doses of cyclophosphamide (CPM) as salvage chemotherapy in patients with metastatic breast cancer
(MBC) pretreated with anthracyclines and taxanes. 41 patients (median age 59 years) with MBC refractory or resistant to anthracyclines and
taxanes were enrolled. The patients’ performance status (WHO) was 0 in 10 patients (24%), 1 in 22 (54%), and 2 in 9 (22%). 30 (73%)
patients had received 2 or more prior chemotherapy regimens. Cyclophosphamide (600 mg m–2) was given i.v. bolus on day 1 and LV
(500 mg m–2 d–1) as a 2-h infusion followed by 5-FU (1.5 g m–2 d–1) over a 22 h c.i. for 2 consecutive days. Cyclophosphamide was
administered every 28 days while 5-FU/LV every 14 days. In an intention-to-treat analysis, complete response (CR) was achieved in 2 (4.9%)
patients and partial response (PR) in 9 (22%) (overall response rate 26.9%; 95% CI: 13.27–40.39%). Stable disease (SD) and progressive
disease (PD) were observed in 9 (22%) and 21 (51%) patients, respectively. The overall response rate was 6% and 40% in patients with
primary and secondary resistance to anthracyclines/taxanes, respectively (P = 0.047). The median duration of response and the median time
to disease progression was 8 and 9.5 months, respectively. The median overall survival was 13 months and the probability for 1-year survival
51%. Grade 3/4 neutropenia occurred in 9 (22%) patients and 4 (9%) patients developed grade 3/4 thrombocytopenia. Non-haematological
toxicity was mild. There were no cases of febrile neutropenia, toxic deaths or treatment-related hospital admissions due to toxicity. The
combination of high-dose 5-FU/LV with conventional doses of cyclophosphamide is a well tolerated and effective salvage regimen in patients
with MBC heavily pretreated with both anthracyclines and taxanes. © 2001 Cancer Research Campaign http://www.bjcancer.com 
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combination with conventional doses of cyclophosphamide as
salvage chemotherapy in MBC pre-treated patients with both
anthracyclines and taxanes. 
PATIENTS AND METHODS 
Eligibility criteria 
Patients with histologically confirmed metastatic breast cancer
were enrolled. All patients had to have either progression during,
or within 6 months of completing anthracyclines and taxanes. In
case of no response during the therapy with these agents, the
patients were deemed to have primary resistance while in case of
objective response for less than 6 months secondary resistance.
Patients who had received anthracyclines or taxanes as adjuvant
therapy were considered to have resistance to these agents and
they were eligible for the study if the disease-free interval was less
than 6 months. Other inclusion criteria were: age 18–75 years;
performance status (WHO) 0–2; bidimensionally measurable
disease; a life expectancy of at least 3 months; adequate hepatic
(serum bilirubin ≤ 1.5 times the upper limit of normal; aspartate
aminotransferase and alanine aminotransferase ≤ 5.0 times the
upper limit of normal) and renal function (serum creatinine
≤ 1.5 mg dl–1); absence of active infection or malnutrition; absence
of a second primary tumour except of adequately treated in situ
carcinoma of the cervix or a non-melanoma skin cancer. Patients
with brain metastases were eligible if they had been irradiated, the
brain lesions were radiographically stable for at least 2 months
post-radiotherapy and clinical improvement was evident. Patients
who had received palliation radiotherapy had to have measurable
metastatic disease outside the radiation fields. Patients with severe
cardiac dysfunction or unstable angina pectoris, or prior irradia-
tion affecting more than 30% of the bone marrow were not
eligible. The protocol was approved by the Scientific and Ethics
Committee of our Institution and all patients gave written
informed consent in order to participate in the study. 
Treatment 
Cyclophosphamide was administered on day 1 at the dose of
600 mg m–2 in 50 ml normal saline by intravenous (iv) infusion
over 15 minutes. Leucovorin (LV) was administered at the dose of 
500 mg m–2 as a 2-hour i.v. infusion, followed by 5-FU at the dose
of 1500 mg m–2 as a 22-hours c.i., repeated on 2 consecutive
days. Cyclophosphamide was administered every 4 weeks, while
5-FU/LV was administered every 2 weeks. Treatment was
continued until disease progression or occurrence of intolerable
toxicity. Dose-modification criteria were based on haematological
and gastrointestinal toxicity. A 25% dose reduction in all drugs
was performed in case of grade 4 granulocytopenia or thrombocy-
topenia lasting for more than 5 days or febrile neutropenia. In case
of ≥ grade 3 diarrhoea, 5-FU/LV doses were reduced by 25% in
subsequent cycles. The treatment on day 15 was also postponed
for a week if the absolute granulocyte count was <1500 dl–1 and
the platelet count < 100 000 dl–1. No prophylactic administration
of growth factors was allowed. 
Evaluation 
Pretreatment evaluation included a detailed medical history and
physical examination, a complete blood cell count with differential
and platelet cell count, whole blood chemistry, determination of
serum levels of carcinoembryonic antigen (CEA) and CA 15-3 
and computed tomography scans of the chest and abdomen.
Additional computed tomography scans and magnetic resonance
imaging scans were performed, if clinically indicated.
Pretreatment evaluation had to be performed within 2 weeks prior
to protocol entry. 
During treatment, whole blood counts with differential and
platelet counts were performed weekly. A physical examination as
well as biochemical tests, determination of serum levels of CEA
and CA 15-3 and chest X-rays were performed every 4 weeks.
Lesions were evaluated after each cycle if they were assessable
by physical examination or by chest X-rays. All patients were
assessed by ultrasound and/or computed tomography scans every
3 cycles using the International Union Against Cancer (UICC)
criteria for response (Monfardini et al 1987). Toxicity was graded
according to the National Cancer Institute common toxicity
criteria (Ajani et al, 1990). 
Statistical consideration 
This was a 2-step phase II study; if an objective response could be
observed in the first 15 patients an additional 15 patients should be
enrolled. The duration of response was measured from the first
documentation of response to disease progression. The time to
tumour progression was determined by the interval between the
initiation of treatment and the date of the first documentation of
disease progression. The follow-up time was measured from the
day of first treatment administration to the last contact or death.
The probability of survival was estimated by Kaplan–Meier
analysis (Kaplan and Meier, 1959), and the confidence intervals
for response rates were calculated using methods for exact
binomial confidence intervals (Cox, 1970). 
RESULTS 
Demographics 
Between October 1997 and February 2000, 41 pretreated patients
with MBC entered the study. Since during the analysis of the first
30 patients the regimen was revealed extremely active, it was
decided to enrol 10 additional patients in order to assess more
accurately the activity of the regimen. Patients characteristics are
shown in Table 1. 32 (78%) patients had a performance status 
0–1, and 26 (63%) were postmenopausal. 9 patients (22%) had
oestrogen receptors (ER)-positive tumours, 10 (24%) ER-negative,
and in 22 (54%) the ER status was unknown. 30 patients (73%)
had received 2 or more chemotherapy regimens for the treatment
of MBC. 18 (44%) and 15 (37%) patients experienced disease with
primary resistance (refractory) to taxanes and anthracyclines,
respectively. 20 patients (49%) had 2 or more metastatic sites and
33 (80%) had visceral disease. 
Response to treatment and survival 
4 patients were not evaluable for response because they discon-
tinued the treatment before tumour evaluation. The reasons for the
early discontinuation of treatment were haemorragic shock due to
disseminated intravascular coagulation (one patient), pulmonary
embolism (one patient), respiratory insufficiency and metabolic
acidosis (one patient) and treatment refusal (one patient). None of
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In an intention-to-treat analysis, 2 (4.9%) patients showed
complete response (CR) and 9 (22%) partial response (PR) for an
overall response rate of 26.9% (95% C.I.: 13.27–40.39%). Stable
disease (SD) and progressive disease (PD) were observed in 9
(22%) and 21 (51%) patients, respectively. All responses were
confirmed by repeated CT scans, and/or U/S within 8 weeks after
their initial documentation. Responses were observed in all
metastatic sites (Table 2) and irrespectively of the treatment line.
In patients with primary resistance to anthracyclines and/or
taxanes, the overall response rate was 6%, while in patients with
secondary resistance 40% (P = 0.047). The 2 CRs were observed
after 4 and 6 courses of chemotherapy and their duration was
9+ and 6+ months, respectively. 
The median duration of response was 8 months (range, 1–20) and
the median time to disease progression 9.5 months (range, 4.5–22.5).
After a median follow-up period of 10.5 months (range, 0.5–27), 25
patients (61%) died; the median overall survival time was 13 months
and the probability for 1-year survival 51% (Figure 1). 
Compliance to treatment 
A total of 192 chemotherapy courses were administered with a
median number of 3 courses per patient (range, 1–18). 13 patients
(32%) received more than 6 courses. The median interval between
courses was 28 days (range, 28–47), and treatment was delayed in
47 courses (24.5%) corresponding to 15 patients (37%) for the
following reasons: haematological toxicity (10 cycles), non-
haematological toxicity (2 cycles) and for miscellaneous reasons
unrelated to the treatment (35 cycles). 
Dose reduction was required in only 4 courses (4%) because of
haematological toxicity. The median administered dose intensity
of cyclophosphamide was 146 mg m–2 week–1 (range, 82–150), of
5-FU 1.412 mg m–2 week–1 (range, 750–1500) and of LV 471 mg m–2
week–1 (range, 250–500). The relative dose intensity was 94% for
cyclophosphamide and 93% for both 5-FU and LV. In 27 patients
(66%) treatment was discontinued because of progressive disease.
One patient refused further treatment after the first cycle. 
Toxicity 
The haematological and non-haematological toxicity of the
regimen is presented in Table 3. The haematological toxicity was
generally mild with 9 (22%) patients developing grade 3/4
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Table 1 Patient characteristics 
No. of patients % 
Patients enrolled  41 
Age (years)
Median 59 
Range 39–75 
Performance status (WHO) 
0 10 24 
1 22 54 
2 9 22 
ER status 
Positive 9 22 
Negative 10 24 
Unknown 22 54 
Prior adjuvant chemotherapy 
Anthracycline-based 10 24 
Non-anthracycline-based 31 76 
Prior regimens for metastatic disease 
1 8 20 
≥ 2 33 80 
Prior treatment with 5-FU/CPM 
5-FU 19 46 
CPM 18 44 
Primary resistance 
To taxanes 18 44 
To anthracyclines 15 37 
Secondary resistance 
To taxanes 23 56 
To anthracyclines 26 63 
Sites of disease 
Visceral disease 33 80 
Non-visceral disease 8 20 
No of metastatic sites 
1 21 51 
≥ 2 20 49 
Table 2 Response according to metastatic site (n = 37) 
No. of patients 
Site CR PR SD PD 
Soft tissues (n = 17) 1 (6%) 5 (29%) 2 (12%) 9 (53%) 
Lymph nodes (n = 13) 1 (8%) 3 (23%) – 9 (69%) 
Liver (n = 17) – 5 (29%) 5 (29%) 7 (42%) 
Pleura (n = 15) – 4 (27%) 3 (20%) 8 (53%) 
Lung (n = 17) 1 (6%) 3 (18%) 3 (18%) 10 (58%) 
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Figure 1 Kaplan–Meier survival curve 
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neutropenia; no patient developed febrile neutropenia and there
was no death due to toxicity. 4 (9%) patients presented grade 3/4
thrombocytopenia and all had received prior radiotherapy for
metastatic bone lesions in an area covering 25% of their bone
marrow. One patient developed grade 3 anaemia. The 
non-haematological toxicity was mild. Grade 3 fatigue was
observed in 3 (7%) patients and grade 3 constipation in one; no
other grade 3 or 4 toxicity was observed. No hospital admission
was required because of treatment-related complications. 
DISCUSSION 
As an increasing number of patients with breast cancer receive
anthracyclines and/or taxane-based chemotherapy as adjuvant or
front-line treatment, the therapeutic options for these patients
when they experience early disease-progression is a difficult task
in oncology practice. Moreover, the total dose of anthracyclines
which has been administered either in the adjuvant setting or in
front-line treatment precludes further administration of this agent
in second-line regimens. In addition, taxane-related neurotoxicity
also makes difficult their use in the second line. Frequently, these
patients have a good performance status and require any effort to
improve, at least, the symptoms of their disease and their quality
of life. 
In this study, by using the combination of continuous infusion 
of 5-FU and cyclophosphamide, 22% of the patients achieved 
an objective response and 27% stabilization of their disease.
However, it is noteworthy that 80% of the patients had visceral
disease and had already received 2 or more chemotherapy regi-
mens based on the most active agents against breast cancer. It is
interesting to note that there was a statistically significant differ-
ence of the overall response rate in patients with primary (ORR =
6%) and secondary resistance (ORR = 40%; P = 0.047), indicating
that this combination should not be prescribed in the former group
of patients. 
The interest in the use of prolonged infusions of 5-FU in the
treatment of breast cancer is not new. In 1987, Hansen et al (1987)
reported an overall response rate of 32%, with a continuous 5-FU
regimen in 5-FU-pretreated patients. The toxicity was significant
but tolerable. Similar results have been reported by other investi-
gators (Chang et al, 1989; Jabboury et al, 1989). Many agents have
been used in combination with continuous 5-FU. Gordon et al
(1990) reported that the combination of protracted infusion of 5-
FU with weekly bolus administration of doxorubicin and oral
cyclophosphamide was associated with an overall response rate of
82% in patients with metastatic breast cancer irrespective of the
prior treatment; however mucositis was the major dose-limiting
toxicity. More recently, Dogliotti et al (1999) reported that the
combination of vinorelbine with protracted infusion of 5-FU
resulted in an overall response rate of 68% (14% CR) in heavily
pretreated patients. Most of their patients had failed or relapsed
after an anthracycline-based first-line chemotherapy regimen and
43% after a taxane-based second-line treatment. The toxicity was
mild as only 2 patients showed grade 4 thrombocytopenia and
grade 3 neurotoxicity, each. In another Italian study, the protracted
infusion of 5-FU in anthracycline refractory breast cancer patients
was associated with a 33% overall response rate and a 6 months
median duration of response (Crivellari et al, 1999). The toxicity
was mild although grade 3–4 hand-foot syndrome occurred in 27%
of the patients. In the same study, the addition of vinorelbine was
associated with an enhanced response rate (ORR: 68%), at the
price of an increased toxicity; toxicity was mostly non-
haematologic as 28% and 21% of the patients showed mucositis
and hand-foot syndrome, respectively. 
In our study, although the patient selection criteria were
different than most of the aforementioned studies, the overall
response rate was significantly lower but the median duration of
response (8 months) and the median time to disease progression
(9.5 months) were encouraging. The 13 months median overall
survival is also promising for these poor prognosis patients. On
the other hand, the toxicity was mild with no grade 3/4 non-
haematological toxicity. It seems that the improved response
rates with the protracted infusion of 5-FU, which have been previ-
ously reported (Dogliotti et al, 1999), were achieved at the price of
increased incidence of mucocutaneous toxicity; however, there
was no benefit in terms of median time to disease progression and
overall survival. Our findings are in agreement with the phase I/II
study, reported by Borguez et al (2000); in this trial the intermit-
tent administration of infusional 5-FU in combination with
vinorelbine resulted in a promising antitumour efficacy with grade
3/4 neutropenia occurring in 39% of the cycles but without grade 3
or 4 non-haematological toxicity. Therefore, it seems that the
intermittent continuous infusion of 5-FU/LV is better tolerated
than the protracted one providing better palliation in heavily
pretreated breast cancer patients. In addition, this regimen does not
require the continuous use of an infusion pump, as well as the
increased expenses related to their use. Although, our patients
were hospitalized for 48 hours in order to receive the 5-FU c.i.,
this could have also been achieved in an out-patient basis using an
indwelling catheter and an infusion pump, thus reducing the cost
of the treatment. The relative utility of this regimen should also be
judged by comparing it with other alternatives such as vinorelbine
or capecitabine which do not require hospital admission or infu-
sional pumps. A cost-effective comparison of our regimen with these
agents is not possible since there are few available data regarding
their activity in this patient population and they are both associated
with significant haematological and non-haematological toxicity. 
In conclusion, the results of the present study demonstrate that
the combination of cyclophosphamide and LV-modulated bolus
plus infusional 5-FU is an active and safe salvage chemotherapy
regimen especially in patients with MBC who have secondary
resistance to anthracyclines and taxanes. However, these data
should be interpreted with caution because of the small number of
patients included in this study. Additional studies are needed in
order to compare the intermittent continuous infusion of 5-FU
with the protracted one in terms of efficacy and tolerance. 
Table 3 Haematological and non-haematological toxicity of patients treated
with CPM+5FU/LV (CI) 
Number of patients (%) 
Toxicity (Grade; NCI) 1 2 3 4 
Neutropenia 10 (24) 7 (17) 4 (10) 5 (12) 
Anaemia 22 (54) 10 (24) 1 (2) – 
Thrombocytopenia 17 (41) – 1 (2) 3 (7) 
Nausea/vomiting 12 (29) 6 (15) ––  
Mucositis 8 (20) 2 (5) ––  
Diarrhoea 4 (10) 1 (2) ––  
Constipation 12 (29) 5 (12) 1 (2) – 
Fatigue 16 (39) 13 (32) 3 (7) – 
Neurotoxicity 4 (10) –––  
Skin reactions 1 (2) –––  
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